Biotechnology company Human Stem Cells Institute opens the book of orders in the framework of its IPO in the MICEX Market for Innovations and Investments
November 12, 2009
On November 12, 2009, Russia’s biotechnology company Human Stem Cells Institute (HSCI) gave its presentation on the MICEX. HSCI intends to make its IPO in the MICEX Market for Innovations and Investments in December 2009.
During the presentation, representatives of the organizer of the offering, ALOR INVEST Company, officially announced the opening of the book of orders to buy shares in HSCI. Co-organizers of the offering are Russian Funds Investment Group and Finam Company.
The forthcoming offering will be the first IPO made by a biotechnology company in the history of Russia’s stock market. HSCI plans to place 15 million shares, representing 20% of the Company authorized capital, at the price of 9 to 11 rubles per share.
The presentation was attended by over 100 people, including representatives of private and state funds, investment banks, management companies and other institutional investors.
According to Gennadii Margolit, Vice-President of the MICEX, “the Exchange is ready to actively assist fast-growing innovation companies in entering the public market and obtaining financing. The emergence of the first issuer from the biotechnology sector is a significant event in the context of the development of an innovation economy in Russia, and it is exactly for this purpose that the MICEX Market for Innovations and Investments was created.”
Brief information:
The MICEX Group is an integrated exchange which provides services related to electronic trading, clearing, settlements as well as depository and information services. The Group is comprised of the MICEX, the MICEX Stock Exchange, the National Mercantile Exchange, the MICEX Settlement House, not-for-profit partnership The National Depository Centre, commercial bank National Clearing Centre (closed joint-stock company), regional exchange centers, regional settlement centers and other organizations. The Group serves over 1700 participants in the on-exchange market – leading Russian banks and broker companies from Moscow and other large financial and industrial centers of Russia. At present, the MICEX Group operates a number of key financial markets: the currency market, the government bonds market, the share market, the market for corporate and regional bonds, the derivatives market and the money market.
ALOR INVEST is the parent company of ALOR Group that has operated in the Russian stock market since 1993 and provides financial services to corporate clients. ALOR INVEST provides brokerage services on all trading floors with personalized service and advanced range of instruments, including the commodity market, and organizes bond issues. ALOR INVEST helps public companies to bring their shares to the exchange and organizes their inclusion in quotation lists. ALOR INVEST also organizes initial public offerings (IPO).
The National Rating Agency (NRA) has assigned ALOR INVEST the ‘AA’ reliability rating (very high reliability, the second level).
Human Stem Cells Institute (HSCI) was established in 2003 to advance projects in stem cell technologies. Today HSCI is an international biotechnology company with laboratories and offices in Moscow, St. Petersburg, Ukraine and Germany. HSCI has modern processing laboratories and storages of cellular material. It has two research laboratories: the Laboratory of Stem Cell Technologies in Moscow and the biotechnological laboratory of SymbioTec Company in Saarbrücken (Germany). The Institute is the main publisher of the journal “Cellular Transplantation and Tissue Engineering”.